Grail announced a partnership on Tuesday to offer its Galleri multicancer early-detection blood test to individuals at Community Health Network’s care sites in central Indiana.
Indianapolis-based Community Health Network, an integrated healthcare system with more than 200 care sites, will become the first such system to offer the Galleri test to patients in its area.
The test, which uses next-generation sequencing and machine-learning algorithms to analyze methylation patterns of cell-free DNA in the bloodstream, is offered to individuals at elevated risk for cancer.